Cite
MLA Citation
M. Schuler et al.. “First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials.” European journal of cancer, vol. 72, n.d., pp. S176–S177. http://access.bl.uk/ark:/81055/vdc_100041521804.0x000049